Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
- Gianni, L.
- Lladó, A.
- Bianchi, G.
- Cortes, J.
- Kellokumpu-Lehtinen, P.-L.
- Cameron, D.A.
- Miles, D.
- Salvagni, S.
- Wardley, A.
- Goeminne, J.-C.
- Hersberger, V.
- Baselga, J.
ISSN: 0732-183X, 1527-7755
Année de publication: 2010
Volumen: 28
Número: 7
Pages: 1131-1137
Type: Article